Researchers from the Karolinska Institute in Sweden and University Children’s Hospital, Ruhr-University-Bochum, Germany, studied the impact of Covid-19 infections on lung function.
AstraZeneca and Amgen’s experimental drug tezepelumab reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.
In a Phase III study, the biologic Dupixent met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.
Sanofi and Regeneron said results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.
A year after Bristol-Myers Squibb walked away from acquiring Promedior and the company’s fibrotic treatment portfolio, Roche stepped in to acquire the biotech firm for up to $1.4 billion.
Vertex Pharmaceuticals Inc. will apply for regulatory approval during 2019 for the company’s triple combination of drugs to treat the life-shortening genetic condition cystic fibrosis.
GlaxoSmithKline Plc said the company’s three-in-one drug Trelegy Ellipta met the main goal of a late-stage asthma study, signaling a possible boost to the British drugmaker’s lung medicines division.
AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.
AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for likely approval in the U.S., where the commercial rights are held by Britain’s Circassia.
GlaxoSmithKline’s inhaled medicine Breo failed to prolong life in patients with chronic respiratory disease in a high-stakes clinical trial of 16,500 people, torpedoing hopes of a sales boost for the drug. Shares in Britain’s biggest drugmaker fell 1.5 percent on Wednesday, lagging a strong London market, in reaction to the news announced by the company […]